[Articles] Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30311-0/fulltext?rss=yes

Once-weekly semaglutide 1·0 mg was superior to daily canagliflozin 300 mg in reducing HbA1c and bodyweight in patients with type 2 diabetes uncontrolled on metformin therapy. These outcomes might guide treatment intensification choices.

Ryan
Ryan

No Comments

Write a Reply or Comment